NCT02988024已完成1 期
A Randomized, Open-Label, Single-Dose Study to Assess the Relative Bioavailability of LY03005 Oral Tablets Versus Pristiq Oral Tablets Under Fasting Conditions in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Area under curve (AUC) for the Pharmacokinetics (PK) of LY03005
研究概览
简要总结
The objects of this study is to assess the relative bioavailability (BA) of 80 mg LY03005 oral tablets compared to 50 mg Pristiq® oral tablets after a single oral intake under fasting conditions in healthy subjects between 18 and 50 years of age.
详细描述
Twenty (20) eligible subjects will be enrolled and assigned to either LY03005 group or Pristiq group at a 1:1 ratio at one site in the USA.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Are capable of giving informed consent and complying with study procedures;
- •Male and female subjects between the ages of 18 and 50 years;
- •Considered healthy by the Principal Investigator, based on a detailed medical history, full physical examination, clinical laboratory tests, 12-lead ECG and vital signs;
- •Nonsmoker, defined as not having smoked or used any form of tobacco in more than 6 months before screening based on subject report;
- •Body mass index (BMI) of 19 to 30 kg/m 2 inclusive and body weight not less than 50 kg;
- •Willing and able to adhere to study restrictions and to be confined at the clinical research center.
- •All female subjects no matter of age must have a negative pregnancy test result at screening. In addition, female subjects must meet one of the following three conditions: (i) postmenopausal for at least 2 years, (ii) surgically sterile based on subject report, or (iii) if child-bearing potential, practicing or agree to practice an effective method of birth control by using an acceptable method of contraception.
- •Acceptable methods of birth control include oral, injected, vaginal or patch contraceptive, IUD (Intrauterine device)(copper intrauterine device), or double- barrier method (e.g., condom, diaphragm or cervical cap with spermicidal foam, cream, gel or suppository). Acceptable methods of birth control must be used for at least 14 days prior to the use of study drug, during the study and within one month after the end of the study.
排除标准
- •Clinically significant past history of gastrointestinal, cardiovascular, musculoskeletal, endocrine, hematologic, psychiatric, renal, hepatic, bronchopulmonary, neurologic, immunologic, lipid metabolism disorders, ophthalmological, or drug hypersensitivity;
- •History of suicide attempt in the past 12 months and/or seen by the investigators having a significant history of risk of suicide or homicide;
- •History or presence of malignancy other than adequately treated basal cell skin cancer;
- •Clinically relevant illness within one month prior to the screening visit or at screening visit that may interfere with the conduct of this study;
- •Subjects with a mean systolic blood pressure of three measurements >140 mmHg, or a mean diastolic blood pressure of three measurements >90 mmHg at screening;
- •Positive blood screen for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibody;
- •A history of seizure. However, a history of febrile seizure is allowed;
- •A hospital admission or major surgery within 30 days prior to screening;
- •Participation in any other investigational drug trial within 30 days prior to screening;
- •A history of prescription drug abuse, or illicit drug use within 6 months prior to screening;
- •A history of alcohol abuse according to medical history within 6 months prior to screening;
- •A positive screen for alcohol, drugs of abuse;
- •Tobacco use within 6 months prior to screening based on subject report;
- •Subjects with hypersensitivity to PRISTIQ or medicines containing desvenlafaxine or its precursor venlafaxine;
- •Subjects who have participated in a previous clinical study of either LY03005 or PRISTIQ or medicines containing desvenlafaxine or its precursor, venlafaxine within 30 days prior to screening;
- •An unwillingness or inability to comply with food and beverage restrictions during study participation;
- •Donation or blood collection of more than 1 unit (approximate 450 mL) of blood (or blood products) or acute loss of blood during the 90 days prior to screening;
- •Use of prescription or over-the-counter (OTC) medications, and herbal (including St John's Wort, herbal teas, garlic extracts) within 14 days prior to dosing (Note: Use of acetaminophen at < 3g/day is permitted until 24 hours prior to dosing).
研究组 & 干预措施
LY03005
Experimental
LY03005 80 mg
干预措施: LY03005 (Drug)
Pristiq
Active Comparator
Pristiq 50 mg
干预措施: Pristiq (Drug)
结局指标
主要结局
Area under curve (AUC) for the Pharmacokinetics (PK) of LY03005
时间窗: 4 days
PK Samples drawn at 0 (within 30 minutes prior to dosing), 1,2,3,4 (+/- 5 min), 6,8,10,12,23,32,48 and 72 hours (+/- 15 min) after dosing.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study of LY03005 vs PristiqMajor Depressive DisorderNCT03733574Luye Pharma Group Ltd.56
已完成
1 期
Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®Major Depressive DisorderNCT03357796Luye Pharma Group Ltd.20
已完成
1 期
A Relative Bioavailability Food Effect Study of LY03005Major Depressive DisorderNCT03822065Luye Pharma Group Ltd.34
已完成
1 期
Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fed Conditions.BioequivalenceDiabetes Mellitus, Type 2NCT06124573Galenicum Health48
已完成
1 期
Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 50 mg /500 mg (FDC) in Healthy Adult Male and Female Subjects Under Fed Conditions.BioequivalenceDiabetes Mellitus, Type 2NCT06124547Galenicum Health48